Lobbying

Horizon Therapeutics USA's latest lobbying report covers Q4 2023, at $60K. Its first report covers Q4 2022; the issues it reports most are Medicare/Medicaid.

Horizon Therapeutics USA

Latest quarter
No record
Q2 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q2 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Horizon Therapeutics USA lobbying by quarter
Horizon Therapeutics USA lobbying by quarter
QuarterAmountReports
Q4 2022$60K1
Q1 2023$60K1
Q2 2023$60K1
Q3 2023$60K1
Q4 2023$60K1
Q1 2024$00
Q2 2024$00
Q3 2024$00
Q4 2024$00
Q1 2025$00
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00

Policy issues the reports name

  • Medicare and Medicaid5 reports

A report that names several issues counts once for each.

Who was lobbied

  • HOUSE OF REPRESENTATIVES5 reports
  • SENATE2 reports

Firms it paid

Firm
Covington & Burling$300K5 quarters

Former officials lobbying for it

Former position
JOHN BYRON MINORLegislative Aide, Policy and Projects Aide, and Staff Assistant, Sen. Kay Hagan; Staff Assistant, Rep. Jim MarshallQ4 2022

Lobbying reports

Filed by
24/01/05for Q4 2023Covington & Burling$60K
23/10/09for Q3 2023Covington & Burling$60K
23/07/14for Q2 2023Covington & Burling$60K
23/04/13for Q1 2023Covington & Burling$60K
23/01/17for Q4 2022Covington & Burling$60K